Skye Bioscience, Inc. (SKYE)
$1.57+2.61%Close
SELLCRISIS · day 57
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $55M
- Beta
- 2.86
- P/E (TTM)
- -0.15
- Short % float
- 0.64%
- Days to cover
- 1.7
- SI change
- +26.4%
- 1W
- -4.85%
- 1M
- -25.59%
- vs SPY 1W
- -4.71%
- vs SPY 1M
- -28.10%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on SKYE?
- LOPJLB’s latest quantitative signal on Skye Bioscience, Inc. (SKYE) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SKYE in?
- Skye Bioscience, Inc. (SKYE) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Skye Bioscience, Inc. (SKYE) do?
- Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company …